相关实验视频

Updated: Jul 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

针对KRAS的天然化合物的分子查:一种针对急性淋巴细胞白血病的多参数策略

Juan Peng¹, Kun Zheng², Lan Ren²

¹Department of Blood Transfusion, Taihe Hospital, Hubei University of Medicine, Shiyan, People's Republic of China.

Journal of enzyme inhibition and medicinal chemistry

|October 9, 2025

概括

研究人员确定了新的非洲天然化合物作为KRAS (G12C) 在急性淋巴细胞白血病 (ALL) 治疗中的潜在抑制剂. 化合物NA/EA-3显示出优异的结合性和稳定性,需要进一步的实验研究.

科学领域:

计算化学和药理学计算化学和药理学
自然产品药物发现自然产品药物发现
血液瘤学血液瘤学

背景情况:

急性淋巴细胞白血病 (ALL) 是一种侵略性癌症,需要新的治疗策略.
准KRAS (G12C) 突变对ALL来说是一个治疗挑战.
探索天然产品为识别新药候选人提供了一个有希望的途径.

研究的目的:

从非洲天然产品数据库中计算识别潜在的KRAS (G12C) 抑制剂,用于ALL治疗.
评估已识别的化合物的结合亲和力,药理动力学特性和安全性.
通过分子动力学模拟和具有约束力的自由能量计算来验证最有前途的候选人.

主要方法:

多参数虚拟选和分子对接 (包括诱导合适对接).
药物动力学和物理化学性质预测 (利宾斯基规则,ADMET分析).
分子动力学模拟和MM/GBSA计算用于稳定性和结合能量的评估.

主要成果:

与索托拉西布相比,六种化合物 (NA/EA-1至NA/EA-6) 的结合亲和力比索托拉西布更强.
所有的化合物都表现出有利的类似药物的特性和无毒的ADMET配置文件.
NA/EA-3表现出异常的稳定性和结合能,表现优于参考抑制剂索托拉西布.

结论:

化合物NA/EA-3是ALL治疗中KRAS (G12C) 抑制剂的非常有前途的候选者.
鉴定到的非洲天然化合物代表了开发新抗癌药物的宝贵资源.
对NA/EA-3的实验验证至关重要,以确认其对ALL的治疗潜力.

关键词:

急性淋巴细胞白血病 (ALL) 是一种疾病.自然的KRAS (G12C) 抑制剂发现药物的发现.分子动力学模拟模拟药物动力学药物动力学

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...